Company: BDRX
Filing Date: 2025-12-08
Form Type: F-1/A
Source: 0001214659-25-017719
Chunk: 161

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-12-08
Form: F-1/A
Chunk 161
---
 and sold outside of the United States to persons who were
neither citizens nor residents of the United States, pursuant to Regulation S, or such sales were exempt from registration under Section
4(a)(2) of Securities Act of 1933, as amended and Rule 506 of Regulation D promulgated thereunder.

On August 3, 2022, we issued
warrants to purchase 16,666 Ordinary Shares to a certain institutional investor at an exercise price of £2.70 per share.

On February 15, 2023, we completed the closing of a private placement pursuant to which we sold to certain institutional investors (1) 3,250,000 Ordinary Shares represented by 32 Depositary Shares at $46,400.00 per Depositary Share, (2) 12,931,020 Ordinary Shares represented by 129 Depositary Shares, issuable upon the exercise of Series A Warrants issued in the private placement at an exercise price of $53,600.00 per warrant, (3) 19,396,400 Ordinary Shares represented by 193 Depositary Shares, issuable upon the exercise of Series B Warrants issued in the private placement at an exercise price of $53,600.00 per warrant, and (4) 62,184,525 Ordinary Shares represented by 621 Depositary Shares, issuable upon the exercise of pre-funded warrants issued in the private placement at an exercise price of $8.00 per warrant, for aggregate gross proceeds of approximately $6.0 million. We also issued unregistered placement agent warrants to purchase a total of 500,000 Ordinary Shares represented by five Depositary Shares toLadenburg Thalmann & Co. Inc., or Ladenburg, at an exercise price of $58,000.00 per warrant, and Series A Warrants to purchase 625,000 Ordinary Shares represented by Depositary Shares at an exercise price of $53,600.00 per warrant to an investor pursuant to a waiver.

| II-1 |

On May 26, 2023, in a private
placement with certain institutional investors, we sold (1) 166,017,700 Ordinary Shares represented by 1,660 Depositary Shares, issuable
upon the exercise of the Series C Warrants at an exercise price of $4,000.00 per warrant, (2) 110,675,600 Ordinary Shares represented
1,098 Depositary Shares issuable upon the exercise of the Series D Warrants at